Beam Targets FDA Approval After AATD Drug Cuts Mutant Protein by 84%

Edgen Stock·Mar 26 2026, 16:37

Share to

Share to

Copy link

Key Takeaways

Beam Therapeutics reported robust Phase 1/2 clinical data for its gene-editing treatment, BEAM-302, demonstrating significant efficacy in patients with Alpha-1 Antitrypsin Deficiency (AATD). The company now plans to pursue an accelerated approval pathway from the U.S. Food and Drug Administration, signaling strong confidence in the drug's potential as a one-time curative treatment.

Potent Efficacy: A single 60 mg dose of BEAM-302 reduced the harmful mutant Z-AAT protein by a mean of 84% and raised protective AAT levels above the therapeutic threshold in all patients.
Regulatory Path: Based on the data, Beam will advance BEAM-302 into a pivotal trial in the second half of 2026 and will seek accelerated FDA approval.
Innovative Science: The treatment uses base editing to correct the underlying genetic mutation, potentially offering a one-time cure that addresses both liver and lung disease associated with AATD.

BEAM-302 Slashes Harmful Protein by 84% in AATD Trial

Beam Therapeutics announced on March 25, 2026, that its base-editing therapy, BEAM-302, showed compelling efficacy in a Phase 1/2 trial for Alpha-1 Antitrypsin Deficiency (AATD). Data from 29 patients showed that the optimal 60 mg dose led to a mean steady-state total AAT level of 16.1 µM, well above the 11 µM protective threshold. Critically, the treatment achieved an 84% mean reduction in the toxic mutant Z-AAT protein, while corrected, functional M-AAT protein comprised 94% of total AAT in circulation. The therapy was well-tolerated, with adverse events being primarily mild to moderate.

Firm Pursues Accelerated FDA Approval with Pivotal Trial in H2 2026

The strong safety and efficacy profile has prompted Beam to select the 60 mg dose for its next stage of development. The company plans to initiate a pivotal cohort in the second half of 2026, enrolling approximately 50 additional patients. Following feedback from the U.S. Food and Drug Administration (FDA), Beam intends to pursue an accelerated approval pathway for BEAM-302, a significant step that could shorten the timeline to market. This pathway will be based on a primary endpoint of AAT biomarkers evaluated over 12 months, de-risking a key asset in the company's pipeline.

These updated results...reinforce the potential for BEAM-302 to become a first- and best-in-class one-time treatment for patients with AATD.

— John Evans, Chief Executive Officer, Beam Therapeutics.